Navigation Links
IDEXX Laboratories to Release 2007 Fourth Quarter and Full-Year Financial Results
Date:1/15/2008

WESTBROOK, Maine, Jan. 15 /PRNewswire-FirstCall/ -- IDEXX Laboratories, Inc. (Nasdaq: IDXX), has scheduled the release of its 2007 fourth quarter and full-year financial results for Friday, January 25, at approximately 7:00 a.m. (eastern). The Company will conduct an analyst conference call beginning at 9:00 a.m. (eastern) on that day.

Individuals can access a live Webcast of the conference call through a link on the IDEXX Web site, http://www.idexx.com. An archived edition of the call will be available after 1:00 p.m. (eastern) on that day via the same link.

The live call also will be accessible by telephone. To listen to the live conference call, please dial 719-325-4782 or 877-723-9502 and reference confirmation code 3405969. Replay of the conference call will be available as of 12:00 p.m. (eastern) on January 25, through Friday, February 1, by dialing 719-457-0820 and referencing replay code 3405969.

About IDEXX Laboratories

IDEXX Laboratories, Inc. is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice-management systems and pharmaceuticals. IDEXX products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 4,500 people and offers products to customers in over 100 countries.

(Logo:

SOURCE IDEXX Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. IDEXX Laboratories to Present at JPMorgan Healthcare Conference
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
4. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Lawsuits Against Several Companies for Patent Infringement
5. RxElite Announces Acquisition of Assets of FineTech Laboratories
6. Parkway Clinical Laboratories Expands Management Team to Support a National Growth Strategy Centered on Oral Fluid Drug Screening
7. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Third Quarter Earnings
8. Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg
9. Roxane Laboratories, Inc. Announces the Launch of Balsalazide Disodium Capsules, 750mg
10. Bedford Laboratories(TM) Announces the Acquisition of CAFCIT(R) (Caffeine Citrate) Injection CAFCIT(R) (Caffeine Citrate) Oral Solution
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... Representatives with Health Food Grocers ... , “Our ‘Ask a Nutritionist’ feature on our website is a free service to ... Brisk, nutritionist and spokeswoman for Health Food Grocers. , Health Food Grocers’ website offers ...
(Date:8/3/2015)... ... ... to an opinion piece published July 28 by the Washington Post, the conventional ... loss may not be accurate. While this system may work for some people, the author ... based both on the individual and at what point that person is in their weight ...
(Date:8/3/2015)... PA (PRWEB) , ... August 03, 2015 , ... ... Africa , Infectious diseases researchers from the University of Pittsburgh School of Medicine ... rollout of HIV prevention drugs in sub-Saharan Africa. , A cooperative agreement ...
(Date:8/3/2015)... FL (PRWEB) , ... August ... ... most-visited bodybuilding and fitness site and the largest online retailer of nutritional ... Awards. BPI Sports is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... Leadership ® and Navigant Center for Healthcare Research and Policy Analysis show widespread ... percent of respondents said they agreed or strongly agreed that the controversial law ...
Breaking Medicine News(10 mins):Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 2Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 3Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3
... to Stem Spread of HIV and Challenge StigmaMENLO ... of leading media companies from Latin America announced ... sobre el SIDA (IMLAS) -- the first Latin ... follows a meeting last month held in conjunction ...
... COLUMBIA, S.C., Feb. 18 /PRNewswire-USNewswire/ -- ... today that its individual clients and U.S. employer ... on surgery and other medical care while remaining ... said his company has accepted the CIMA Hospitals ...
... Columbia, Feb. 18 ,Allscripts announced today that Edge ... to resell the Allscripts Electronic,Health Record as "EdgeEHR(TM) ... currently use practice management software on the Mac ... http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) , ...
... to Personalized Screening of Anti-Rejection Drug DosingCINCINNATI, Feb. ... that helps the body metabolize a kidney transplant ... higher risk for side effects, including compromised white ... new research.Published online Feb. 18 by the Nature ...
... winners of the MetLife Foundation Awards for Medical ... Washington, D.C. today, at a scientific briefing and luncheon that ... understanding of Alzheimer,s and the substances in the brain that ... Michael S. Wolfe , Ph.D., professor of neurology at ...
... Gene Function to Double Survival and Increase Transfusion IndependenceCROSSWICKS, ... Myelodysplastic Syndromes (MDS) Foundation says data published in the ... confirms VIDAZA extends survival for patients with higher-risk MDS. ... are difficult to treat and in higher-risk patients have ...
Cached Medicine News:Health News:Top Latin American Television Companies Commit to Addressing AIDS 2Health News:Top Latin American Television Companies Commit to Addressing AIDS 3Health News:Top Latin American Television Companies Commit to Addressing AIDS 4Health News:Companion Global Healthcare Expands Service to Include Hospitals in Mexico 2Health News:Edge Health Solutions Selects Allscripts Electronic Health Record for Apple Mac OS X Medical Platform 2Health News:Edge Health Solutions Selects Allscripts Electronic Health Record for Apple Mac OS X Medical Platform 3Health News:Edge Health Solutions Selects Allscripts Electronic Health Record for Apple Mac OS X Medical Platform 4Health News:Edge Health Solutions Selects Allscripts Electronic Health Record for Apple Mac OS X Medical Platform 5Health News:Gene Mutation Increases Drug Toxicity, Rejection Risk in Pediatric Kidney Transplants 2Health News:Gene Mutation Increases Drug Toxicity, Rejection Risk in Pediatric Kidney Transplants 3Health News:Gene Mutation Increases Drug Toxicity, Rejection Risk in Pediatric Kidney Transplants 4Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 2Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 3Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 4Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 5Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 6Health News:Video: The MDS Foundation Says Published Data Confirms VIDAZA(R) Significantly Extends Survival in Patients with the Malignant Condition MDS 2
(Date:8/3/2015)... -- Ortho Clinical Diagnostics (OCD) today announced that ... and Communications Officer, effective immediately. As the newest member ... the company,s worldwide corporate brand and communication strategies as ... company by adding sites in countries outside the U.S. ... Dr. Martin Madaus . Since becoming ...
(Date:8/3/2015)... Global physiotherapy equipments ... 24.7 billion by 2022, according to a new ... of neurological and musculoskeletal disorders are expected to ... period. The presence of efficient and effective therapies ... technologies coupled with implementation of favorable government policies ...
(Date:8/3/2015)... ANGELES, Aug. 3, 2015  CytRx Corporation (NASDAQ: ... in oncology, today reported financial results for the three ... overview of recent accomplishments and upcoming milestones for its ... 2015 has been very productive for CytRx. Enrollment in ... aldoxorubicin in soft tissue sarcoma (STS) continues on track ...
Breaking Medicine Technology:Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14
... Dec. 4 Long-term data published in,EuroIntervention showed ... (MVA),after repair with the MitraClip(R) system to correct ... mitral stenosis. Additionally,with two years of follow-up, none ... surgery for mitral stenosis. At 12 months no,important ...
... newly diagnosed patients with a life-threatening type of leukemia to be ... , - Exjade results at ASH to show benefits ... damage key organs , , - ... to report on optimal post-surgery treatment strategy, Femara vs. tamoxifen , ...
Cached Medicine Technology:Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: